Clinical molecular testing has been available for 22q11.2 deletion syndrome (22q11.2DS) for over two decades yet under-recognition and diagnostic delays are common. To characterize the "diagnostic odyssey" in 22q11.2DS we studied 202 well-characterized unrelated adults, none ascertained through an affected relative. We used a regression model to identify clinical and demographic factors associated with length of time to molecular diagnosis. Kaplan-Meier analysis compared time to diagnosis for the molecular testing era (since 1994) and earlier birth cohorts.
| I N TR ODU C TI ON
22q11.2 deletion syndrome (22q11.2DS) (MIM #192430/188400), previously known as DiGeorge or velocardiofacial syndrome, is the most common microdeletion syndrome, with an estimated prevalence of over 1 in 4,000 live births (Goodship, Cross, LiLing, & Wren, 1998; McDonaldMcGinn et al., 2015; Oskarsdottir, Vujic, & Fasth, 2004) . Associated manifestations include classic developmental features such as birth defects and intellectual disability, and later onset features such as schizophrenia (Bassett et al., 2011; Fung et al., 2015; McDonald-McGinn et al., 2015) .
Variable expression across the lifespan involves multiple organ systems, with substantial morbidity and mortality, beginning prenatally (Bales, Zaleski, & McPherson, 2010; Bassett et al., 2005 Bassett et al., , 2009 Bassett et al., , 2011 Bassett, Costain, & Marshall, 2017; Cheung et al., 2014; Costain, Chow, Ray, & Bassett, 2012; Fung et al., 2015; Gerdes, Solot, Wang, McDonald-McGinn, & Zackai, 2001; McDonald-McGinn et al., 2015) . Penetrance for one or more of the many associated features is high; typical 22q11.2 deletions are not found in large population control samples (Cooper et al., 2011) . Molecular testing has been available for over 20 years using fluorescence in situ hybridization (FISH) and a probe that targets the typical deletion 22q11.2 locus (Driscoll et al., 1993) . More recently, genomewide methods, for example, microarray, have become the clinical standard, recommended for all individuals with developmental delay/ intellectual disability, multiple congenital anomalies, and/or autism (Miller et al., 2010) . Despite widespread availability of molecular testing, multiple factors including under-recognition of 22q11.2DS could limit implementation of these best practices, contributing to diagnostic delays, or "odysseys," for patients and their families (Bassett et al., 2011; Fung et al., 2015; McDonald-McGinn et al., 2015) .
Information about the pathways to a diagnosis of 22q11.2DS may inform strategies to reduce time to molecular testing, and facilitate the identification of individuals who remain undiagnosed. In this study, we examined the "diagnostic odyssey" of a well-characterized cohort of 202 unrelated Canadian adults with 22q11.2DS who came to attention as the first in the family to receive a molecular diagnosis. We aimed to identify factors associated with time to molecular diagnosis. We hypothesized that, in addition to the presence of major congenital or developmental features, that is, congenital heart disease (CHD), palatal anomalies and developmental delay/intellectual disability (DD/ID), availability of molecular testing at birth would be associated with a significantly shorter time to molecular diagnosis compared with individuals where the emergence of molecular testing capability became available during childhood or adulthood. We also evaluated the relationship between the number of specialties seen and the length of time to diagnosis. To enhance power for the main analysis, we subsequently obtained data from a comparably characterized cohort of unrelated individuals with 22q11.2DS from another major center. The main sample comprised 202 adults with 22q11.2DS (n 5 98 male, 48.5%; median molecular diagnostic age 17.3 years, range 0.1-59.4 years) who met the following inclusion criteria with respect to molecular diagnosis: (a) typical 22q11.2 deletion detectable by a standard probe using FISH (n 5 191, 94.6%) or clinical genome-wide microarray (n 5 11, 5.4%) (Bassett et al., 2005; Bassett, Marshall, Lionel, Chow, & Scherer, 2008) , and (b) diagnosis made prior to that of any other affected family member. Ethnicity was characterized as European (n 5 159, 78.7%) or non-European descent, the latter comprising Asian (n 5 14, 6.9%), African (n 5 7, 3.5%), or other (n 5 22, 10.9%) including mixed ethnicity. Patients were ascertained through a specialty clinic for adults with 22q11.2DS (The Dalglish Family 22q Clinic for Adults) or the Clinical Genetics Research Program in Toronto, Canada. Ascertainment of this sample followed active screening for 22q11.2DS at an adult congenital cardiac clinic (n 5 75) or referrals through genetics (n 5 68), psychiatric (n 5 40), or other (n 5 19) sources (Bassett et al., 2005 (Bassett et al., , 2008 Bassett, Caluseriu, Weksberg, Young, & Chow, 2007; Cheung et al., 2014) . Molecular diagnosis originated in Ontario for most (n 5 180, 89.1%) subjects; the remainder were from other provinces. Informed consent was obtained in writing, and the study was approved by local research ethics boards.
To assess the impact of molecular testing availability for the 22q11.2 deletion on time to diagnosis, we divided the sample into three birth-cohort subgroups based on when molecular testing for the typical 22q11.2 deletion using FISH and a targeted probe became widely available (Driscoll et al., 1993) , that is, in 1994. These three birth cohorts comprised Group 1 (n 5 53, 26.2%) born before 1977 (i.e., testing became available in adulthood years), Group 2 (n 5 108, 53.5%) born 1977-1993 (i.e., testing became available in childhood years), and the index group, Group 3 (n 5 41, 20.3%) born 1994-1997 inclusive (i.e., born in the molecular testing era).
For this Canadian sample, comprehensive data on demographic and clinical features, and on the genetic diagnostic pathway, were recorded from birth to molecular diagnosis from available lifetime medical records collected by our program, and extensive clinical histories obtained from the patient and collateral sources (typically family members) at multiple time points (Bassett et al., 2005 (Bassett et al., , 2007 (Bassett et al., , 2008 Cheung et al., 2014 ). We used previously described standard methods to classify congenital cardiac and palatal anomalies (Bassett et al., 2005; Billett, Cowie, Gatzoulis, Vonder Muhll, & Majeed, 2008) , 2015) . There were 82 subjects with CHD of moderate to severe complexity (e.g., tetralogy of Fallot) and 34 with mild complexity (e.g., ventricular or atrial septal defect) (Billett et al., 2008) . There were 87 subjects with velopharyngeal insufficiency (VPI), including 66 with VPI plus another palatal anomaly, 15 subjects with submucous cleft or short palate only, and none with overt cleft palate only. DD/ID was at the mild (n 5 94) or moderate/severe (n 5 20) level; the other subjects (n 5 88) were at the borderline to average intellectual level (Butcher et al., 2012; Chow et al., 2006; Van et al., 2015) .
| Philadelphia (US) sample
We obtained additional data from 112 comparably characterized individuals with 22q11.2DS followed at a major U.S. center, the Children's Hospital of Philadelphia. An additional 51 adults (n 5 19 male, 37.3%; median diagnostic age 2.9, range 0-17.6 years) brought the sample size of Group 3 to n 5 92. A further 61 subjects comprised a new pediatric comparison subgroup (Group 4: born in 1998 and thereafter).
For the U.S. adult cohort (n 5 51), there were 18 subjects with CHD of moderate to severe complexity and 13 with mild complexity (Billett et al., 2008) ; 33 subjects had VPI, including 9 with VPI plus another palatal anomaly, 7 had submucous cleft or short palate only, and 1 overt cleft palate only; DD/ID in 21 subjects was at the mild (n 5 15) or moderate (n 5 6) level; the other subjects (n 5 9) were at the borderline to average intellectual level.
| Statistical analyses
We constructed a multivariable linear regression model to examine potential contributors to time to molecular diagnosis of 22q11.2DS (i.e., "diagnostic delay"), defined as the number of years to molecular diagnosis from either 1994 (the year clinical FISH testing was widely available to the samples studied) or year of birth (given the importance of early diagnosis; Bales et al., 2010; Bassett et al., 2017; Cheung et al., 2014; Costain et al., 2012; McDonald-McGinn et al., 2015) , whichever came later. The variables selected, in addition to the birth-cohort subgroups, ethnicity and sex, were three classic developmental features of 22q11.2DS (cardiac anomaly, palatal anomaly, and DD/ID). We opted not to include dysmorphic features due to inconsistent documentation in medical records of these often subtle features in 22q11.2DS (Liu et al., 2014; Veerapandiyan et al., 2011) .
Kaplan-Meier curves were constructed to assess time to diagnosis for the different birth-cohort subgroups. To enhance the power to determine whether being born in the molecular era reduced diagnostic delay in the regression and Kaplan-Meier analyses we used the additional adult and pediatric data from the U.S. center (total North American sample n 5 314, n 5 253 for Groups 1-3). In a second analysis, a log rank test (uncorrected for other factors) was used to compare the Kaplan-Meier curves.
To better examine the clinical pathway to a molecular diagnosis of 22q11.2DS, we used a representative subset of the Canadian sample (total n 5 100; n 5 52 male; median diagnostic age 14.3 years, range 0.1-58.2 years) to examine detailed data available on the clinical services involved prior to molecular diagnosis. The three birth-cohort subgroups were matched on demographic and clinical data for the three classic developmental features used in the main regression analysis. Proportionate representation (Group 1, n 5 26, 26.0%; Group 2, n 5 53, 53.0%; Group 3, n 5 21, 21.0%) was comparable to that for the total Canadian sample (n 5 202). To examine the relationship of the number of different specialty areas to the time to molecular diagnosis, we comprehensively recorded additional 22q11.2DS-associated features (Bassett et al., 2009 (Bassett et al., , 2011 Fung et al., 2015; McDonald-McGinn et al., 2015) noted in medical records prior to molecular diagnosis, the number and type of clinical specialty areas (both medical and allied health) in which the patient was seen for these features, any other consults related to these specialty areas, and any other genetic syndromes that were documented as being suspected. Specialty areas recorded included pediatric and adult medical and surgical subspecialties, and the specialty area of the clinician who ordered the molecular diagnostic test. Family doctors and pediatricians were not included in the medical specialties count as it was assumed that all individuals would have been seen by these primary care clinicians in the Canadian Medicare system. Also excluded were emergency room physicians and the areas of radiology and anesthesia, although most patients would have had contact with these specialty areas. The regression analysis for diagnostic delay was repeated for this subset of 100 subjects, adding the number of clinical specialties seen prior to molecular diagnosis as a new factor.
All statistical analyses were two-tailed with statistical significance defined as p values <.05, performed with SAS 9.4 software (SAS Institute, Cary, NC).
| RE S U L TS
The median time to molecular diagnosis for the 202 Canadian adult subjects with 22q11.2DS was 4.7 (range 0.0-20.7) years. Most adults (n 5 191; 94.6%) had one or more classic developmental feature of 22q11.2DS: cardiac or palatal anomalies or DD/ID. The median time to molecular diagnosis for the representative subset of 100 Canadian adult subjects was similar (4.5, range 0.0-19.5, years). Table 1 shows the selected clinical and demographic features of the sample and their relationship to the time to molecular diagnosis of 22q11.2DS. The regression model for time to molecular diagnosis for the Canadian sample was significant (adjusted R 2 5 0.16, df 5 6, p < .0001). Consistent with our hypothesis, palatal and cardiac anomalies were significantly associated with a shorter time to molecular diagnosis, however DD/ID was not a significant factor (Table 1) . Also, non-European ethnicity was significantly associated with a longer time to molecular diagnosis ( Table 1) .
| Demographic and selected clinical features associated with time to molecular diagnosis
The log rank test for the Kaplan-Meier curves (Figure 1 ) for the three Canadian birth-cohort subgroups (n 5 202) showed a nonsignificant trend toward a shorter time to diagnosis for the group born during the molecular testing era (Group 3) (p 5 .082; Figure 1a ) compared with the other two subgroups.
For the combined North American sample (n 5 253), results using the same regression model were similar, but with the enhanced power afforded by the additional Group 3 subjects, a significantly shorter time to molecular diagnosis for this group became evident (p 5 .016, Table   1 ). The log rank test for the Kaplan-Meier analysis comparing the survival curves of the three groups also became significant (p 5 .0005), with significant between-group differences for Groups 1 and 3 (p 5 .0095) and Groups 2 and 3 (p 5 .0009). The overall Kaplan-Meier analysis was also significant (p < .0001, Figure 1b) after the further addition of Group 4 (61 U.S. pediatric subjects born 1998 and thereafter), with significant additional between-group differences for Groups 1 and 4 (p < .0001) and 2 and 4 (p < .0001).
Notably, only a minority of patients at either center born in the molecular era were diagnosed in their first year of life (13/ Figure S1 ). Even for those with CHD (with or without palatal anomalies or DD/ID), a substantial minority had diagnostic delays of over 2 years (10/22, 45.5% and 23/68, 33 .8% in the Canadian and U.S. molecular era [Group 3] cohorts, respectively). For those born in the molecular era with palatal anomalies and/or DD/ID, but without CHD, the majority had diagnostic delays of over 2 years (13/14, 92.9% and 25/34, 73 .5% in the Canadian and U.S. Group cohorts, respectively).
| Clinical pathway to molecular diagnosis
The detailed data available for the Canadian cohort subset (n 5 100)
indicated that in addition to the classic developmental features, there were a total of 22 other clinical features of 22q11.2DS documented prior to molecular diagnosis ( Table 2 ) at visits that involved a total of 26 specialty areas (Supporting Information Table S1 ). The median number of specialty areas seen per subject prior to molecular diagnosis was 7 (range 2-15). The regression model remained significant with the additional variable of specialty areas seen (adjusted R 2 5 0.22, df 5 7, p < .0001). Results for the other variables were similar to those for the entire sample (Supporting Information Table S2 ). Contrary to expectations, the number of specialty areas seen before diagnosis was significantly associated with a longer time to molecular diagnosis of 22q11.2DS (B 5 0.46, p 5 .0088; Supporting Information Table S2 ).
Molecular testing that led to a diagnosis of 22q11.2DS was ordered primarily by genetics specialists (n 5 62, 62%) followed by cardiologists (n 5 15, 15%), pediatricians/family doctors (n 5 12, 12%), and other specialists (Supporting Information Table S1 ). For 26 of these 100 subjects, one or more of 9 other genetic syndromes was documented as being considered prior to the molecular diagnosis of 22q11.2DS: Fragile X (n 5 9), cri-du-chat (n 5 2), Down (n 5 2), Rubinstein-Taybi (n 5 2), Turner (n 5 2), and one each of Marfan, Noonan, Pierre-Robin, and Williams; five individuals were said to have an "indeterminate" genetic condition.
| D ISC USSION
This study provides novel in-depth data on the pathways to molecular diagnosis for the current generation of individuals living with 22q11.2DS. Despite its prevalence and high penetrance for major associated features requiring medical attention (Bassett et al., 2011; Fung et al., 2015; McDonald-McGinn et al., 2015) , 22q11.2DS has historically been a significant diagnostic challenge for clinicians (Fung et al., ). The regression model for time to molecular diagnosis for the Canadian sample was significant (adjusted R 2 5 0.16, df 5 6, p < .0001). The regression model for time to molecular diagnosis for the combined North American sample was significant (adjusted R 2 5 0.20, df 5 6, p < .0001). a Multivariable linear regression model for length of time to molecular diagnosis of 22q11.2DS, defined as the number of years from the earliest opportunity for molecular diagnosis (i.e., number of years from 1994 or year of birth, whichever came later, to the year of molecular diagnosis. b Group 3 5 index group born 1994-1997 inclusive (i.e., born in the molecular testing era), compared with Groups 1 (n 5 53, 26.2%, born before 1977, i.e., testing became available in adulthood years) and 2 (n 5 108, 53.5%, born 1977-1993, i.e., testing became available in childhood years).
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2015; Veerapandiyan et al., 2011) . The results of the current study indicate that this remains the case, even in major 22q11.2DS centers of expertise and over 20 years after molecular testing for the typical associated 22q11.2 deletion became widely available. Together with previous studies (Bales et al., 2010; Cheung et al., 2014; McDonald-McGinn et al., 2015) , the findings support the need for improved clinical recognition of and testing for the syndrome, and for the implementation of newborn screening for 22q11.2DS.
FIG URE 1
Length of time to molecular diagnosis of 22q11.2 deletion syndrome (22q11.2DS) for three sub-groups in (a) a Canadian and (b) a combined North American cohort. Kaplan-Meier curves showing time to molecular diagnosis of 22q11.2DS for individuals born in the era of molecular testing (Group 3, gray dotted line), that is, 1994-1997 inclusive, and for individuals who were children (Group 2, red solid line) or were adults (Group 1, blue dashed line) in the molecular era. (a) The median time to diagnosis was 3.8 years (range 0.1-19; 95% CI 2.1-4.7 years) for the 41 subjects born in the era of molecular testing (Group 3), the median diagnostic delay was 4.9 years (range 0.1-20.7 years; 95% CI 3.5-6.7 years) for those who were children (Group 2), and 5.7 years (range 0-18.5 years; 95% CI 4.2-7.9 years) for those who were adults (Group 1). The log rank test showed there was no significant difference between these curves (p 5 .082). There were no censored values. (b) After adding 51 U.S. subjects to Group 3, the median diagnostic delay was 3.3 years (range 0-19.0 years; 95% CI 2.1-4.2) for the total 92 subjects born in the era of molecular testing. Also shown is Group 4 (n 5 61 pediatric U.S. subjects born in 1998 and thereafter, green double dash line), with a median diagnostic delay of 1.6 years (range 0-12.3 years; 95% CI 0. 6-2.3 years). There were two censored values each in Groups 3 and 4 where the "event" of interest, a molecular diagnosis of 22q11.2DS, occurred at birth (i.e., diagnostic age 0). The log rank test revealed significant differences overall when comparing the survival curves of the four groups (p < .0001). Subsequent comparisons of these four curves were made with Bonferroni's correction for multiple comparisons. Significant differences were found between Groups 1 and 3 (p 5 .0043), 1 and 4 (p < .0001), 2 and 3 (p 5 .0011), and 2 and 4 (p < .0001). There were no significant differences between Groups 1 and 2 (p 5 .99) or 3 and 4 (p 5 .63)
The results are consistent with previous findings of earlier diagnosis in the presence of physical congenital anomalies of the heart and/or palate that are considered typical of 22q11.2DS (Cancrini et al., 2014; Gerdes et al., 2001; Grassi et al., 2014; McDonald-McGinn et al., 2015) . However, our results also indicated that many individuals with classic features of 22q11.2DS still experienced notable delays in molecular diagnosis. Given the highly variable expression of 22q11.2DS and the results of this and other studies (Fung et al., 2015; Liu et al., 2014; Veerapandiyan et al., 2011) , it would appear that over-reliance on the presence of "classic" features may be inadequate for optimizing diagnostic practice for 22q11.2DS. Our findings indicate this may be especially the case for those of non-European ancestry, consistent with previous studies of African American and Chinese patient samples (Liu et al., 2014; Veerapandiyan et al., 2011) . The results for ethnicity also provide indirect support for evidence from other studies that relying on the presence of "characteristic" minor dysmorphic features and/or facial gestalt is insufficient for optimal decision-making about genetic testing or referral in this highly variable syndrome (Becker et al., 2004; Liu et al., 2014; McDonald-McGinn et al., 2015; Veerapandiyan et al., 2011) .
Findings from this study show that, although there is evidence of some improvement over time, there continue to be notable delays even for those born in the era of molecular testing and followed at prominent medical centers. Only a minority received a diagnosis in the first few years of life. There was no significant difference observed in length of time to molecular diagnosis between adult and pediatric (i.e., younger) subjects born in the molecular era. Collectively, the results support a need for further advances in reducing diagnostic delays.
Newborn screening has been proposed for 22q11.2DS (Bassett et al., 2011; Fung et al., 2015; McDonald-McGinn et al., 2015) . Although multiple criteria must be met prior to implementation, newborn screening would remove the identification bias related to classic features, including those obvious prenatally or at delivery, and ensure timely care and preventive measures for all individuals with 22q11.2DS and their families. The findings of the current study support the necessity of newborn screening to achieve such aims.
Contrary to our expectations, the presence of DD/ID in our sample was not associated with a shorter time to molecular diagnosis of 22q11.2DS. Under-recognition of 22q11.2DS as a common cause of all types of developmental delays (Bassett et al., 2011; McDonald-McGinn et al., 2015) may be a factor. Clinical microarrays are now the first line investigation recommended for those with DD/ID and other major developmental conditions (Miller et al., 2010) bronchitis/pneumonia, n 5 22; sinusitis, n 5 11. Recurrent defined as two or more of any infection or documented in records as "recurrent" or "frequent" of any infection. d Included poor suck, nasal regurgitation, "sweaty/distressed" when feeding or if "feeding difficulties" were noted in records. e Included scoliosis, kyphosis, lordosis.
f One or more seizures. g Schizophrenia (n 5 23), psychotic mood disorder (n 5 1). h Excluded subjects with palatal anomalies. i Included myopia, strabismus, keratoconus, glaucoma, amblyopia, astigmatism, and those with unspecified vision problems. j Symptoms of both depression and anxiety (n 5 6), anxiety only (n 5 6) or depression only (n 5 6) were noted by a professional, though a clinical diagnosis of these affective disorders was not made in all cases prior to molecular diagnosis of 22q11.2DS. Heussler, 2014). These DD/ID results thus provide further support for newborn screening.
To our knowledge, the results of this study provide the first evidence that having more clinical specialty areas involved in patient care
could actually be associated with a longer time to molecular genetic diagnosis. Tautology (e.g., that the more challenging patients with delayed diagnosis see more specialties) appears unlikely to explain all cases, given the high numbers of specialty areas for most patients. It is possible that some specialists were uncertain as to how to refer for diagnostic testing. The finding that genetic specialists most commonly ordered diagnostic testing suggests that some of the diagnostic delay could be in the time to be referred to and be seen by a geneticist.
Genetics referrals could also indicate unfamiliarity among other specialties with directly ordering genetic tests (Dominguez-Carral et al., 2017; Haga, Burke, & Agans, 2013; Press, Wieczorek, Hoover-Fong, Bodurtha, & Taylor, 2016; Salm et al., 2014) , even though access to genetic testing for 22q11.2 deletions by licensed physicians in Ontario is universal. In many jurisdictions, insurance and other barriers, including additional forms and requirements, may limit genetic test capabilities and uptake. It is possible that some specialists had no suspicion of a genetic condition. Awareness of 22q11.2DS by pediatricians and teachers, including its associated physical, cognitive, and behavioral features, is reported to be lower than that for other genetic syndromes (Lee et al., 2005) . One could also speculate about other factors that could contribute to the finding. There are general issues with clinicians operating within "silos" of medical expertise (De Hert et al., 2011; Horvitz-Lennon, Kilbourne, & Pincus, 2006) , and the many terms (e.g., velocardiofacial and DiGeorge syndrome) for 22q11.2DS that may contribute to confusion regarding molecular diagnosis, best practice guidelines, and access to information and support services (Busse et al., 2011 McKay et al., 2017; Mordaunt et al., 2014) , and family physicians and other primary care providers who could "put the puzzle pieces together" for undiagnosed patients.
| Study advantages and limitations
We had access to a well-characterized cohort of adults with 22q11.2DS with long-term phenotypic data and were able to obtain comparable data from another major 22q11.2DS center. Such systematically collected data are rare. However, in addition to the sample size and related power issues, our findings are limited by patient were similar, and the fact that the majority of the subjects were from major 22q11.2DS centers would make it likely that the findings are conservative, close to best case with respect to availability and implementation of molecular testing. Generalizability to other jurisdictions with slower roll-out or barriers such as additional requirements before testing (e.g., medical genetics referral, specific features) therefore would likely tend to be in the same direction of the findings. This would also be expected to be the case where ascertainment bias was greater, for example, even higher prevalence of major congenital features such as CHD than in the current study. Testing and subsequent diagnosis of 22q11.2DS remains heavily reliant on identification of classic features of the syndrome, likely influencing the findings. This would also pertain to dysmorphic features not included in the current study.
Using intellectual disability as a proxy for clinically relevant developmental delay has limitations given that an ID diagnosis is made after the newborn period. However, nearly all individuals with an ID also have documented developmental delays (Doherty et al., 2013) and only a small proportion of the cohort had ID/DD but no major physical congenital anomalies. Also, we found that a diagnosis of ID/DD for any subgroup (pediatric to adult), did not shorten time to diagnosis. Time of molecular diagnosis was defined as that recorded in the available medical records confirmed with lab results. The length of time to "disclose" the diagnosis of 22q11.2DS to patients and families may be longer than the time to molecular confirmation reported here, for example, related to lack of follow-up by treating clinicians in some cases and missed appointments by these relatively complex patients. Strategies for disclosing and discussing a diagnosis of 22q11.2DS have been previously described (Bassett et al., 2011; Cancrini et al., 2014; Costain et al., 2012; Fung et al., 2015) .
| CON CL U S I ONS
The variable phenotype of 22q11.2DS continues to present a significant diagnostic challenge to clinicians, more than 20 years after the introduction of molecular testing. Diagnostic delays can correspond to delayed access to appropriate anticipatory care, early interventions, and access to resources and services including genetic counseling and family planning (Cotter et al., 2016; Pfundt et al., 2017; Press et al., 2016) . Implementation of 22q11.2DS as the single diagnostic label, provision of timely confirmatory molecular testing, and increased use of clinical microarrays as a first-tier test for those with developmental delays/intellectual disabilities and/or congenital anomalies may improve confidence in ordering genetic testing and help to reduce diagnostic confusion while eliminating missed or prolonged diagnosis for patients with 22q11.2DS and their families (Sagoo et al., 2015; Trakadis & Shevell 2011) . Understanding and preventing delays in diagnosis may reduce the burden of disease and improve symptom management, patient long-term outcome, and lower overall health care costs. Prenatal detection is also likely to decrease morbidity and even neonatal mortality (Grati et al., 2015) . Despite availability of genetic testing, the diagnostic odyssey faced by patients with 22q11.2DS and their family members continues prolonged in many cases. Increased awareness and education, but especially the advent of newborn screening, could prevent these unnecessary diagnostic odysseys. Clinic was founded by a grant from the W. Garfield Weston
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